Nathan Karin

USPTO Granted Patents = 20 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

16 out of 34

Rappaport Family Institute for Research in the Medical Sciences

patents

2 out of 945

Technion Research & Development Foundation Limited

patents

1 out of 1

Rapport Family Institute for Research in the Medical Sciences

patent

4. 1 out of 1

Rappaport Family Institute for Research in the Medical Services

patent

Years Active: 2001-2021

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10975122 - Epitope as a target for therapy of inflammatory autoimmune diseases and graft rejection (2021-04-13),

2. 9717777 - Use of CCL1 in therapy (2017-08-01),

3. 9670282 - Compositions and methods for diagnosing and treating an inflammation (2017-06-06),

4. 9611324 - Compositions and methods for diagnosing and treating an inflammation (2017-04-04),

5. 9371385 - Compositions and methods for diagnosing and treating an inflammation (2016-06-21),

6. 9352000 - Use of CCL1 in therapy (2016-05-31),

7. 9145460 - Compositions and methods for diagnosing and treating an inflammation (2015-09-29),

8. 9023349 - Compositions and methods for diagnosing and treating an inflammation (2015-05-05),

9. 8658375 - Compositions and methods for diagnosing and treating an inflammation (2014-02-25),

10. 8512698 - Compositions and methods for diagnosing and treating an inflammation (2013-08-20),

11. 8486641 - Compositions and methods for diagnosing and treating prostate cancer (2013-07-16),

12. 8486396 - Compositions and methods for diagnosing and treating an inflammation (2013-07-16),

13. 8409569 - Compositions and methods for diagnosing and treating an inflammation (2013-04-02),

14. 8388962 - Molecules and methods of using same for treating MCP-1/CCR2 associated diseases (2013-03-05),

15. 8263064 - Method of suppressing disease severity of multiple sclerosis using chemokine CXC11 (2012-09-11),

Title: Nathan Karin: Innovator in Therapeutic Peptides and Immune Modulation

Introduction

Nathan Karin is a distinguished inventor based in Haifa, Israel, known for his groundbreaking work in the field of immunology and peptide therapies. With an impressive portfolio of 20 patents, he has significantly contributed to the understanding and treatment of inflammatory autoimmune diseases and graft rejection.

Latest Patents

Among Nathan's latest patented innovations is a peptide that targets an epitope within the macrophage scavenger receptor B-I. This invention provides a method for utilizing this peptide, as well as the nucleic acid encoding it, along with an antibody that binds to the epitope. Another notable patent outlines the use of CCL1 in therapy, describing a method for treating conditions where suppression of effector T cells is advantageous, by administering a therapeutically effective amount of a CCL1 polypeptide to the subject.

Career Highlights

Nathan has made significant strides in his career, holding positions at renowned institutions such as the Rappaport Family Institute for Research in the Medical Sciences and the Technion Research & Development Foundation Limited. His work has been pivotal in advancing therapeutic approaches in medicine, particularly in targeting inflammatory conditions.

Collaborations

Throughout his career, Nathan has collaborated with esteemed colleagues such as Gizi Wildbaum and Yaniv Zohar. These partnerships have been instrumental in driving forward research initiatives and fostering innovation in therapeutic development.

Conclusion

Nathan Karin stands out as a prominent inventor in the field of immunology, with a strong focus on therapeutic peptides and immune response modulation. His contributions through multiple patents underscore his commitment to advancing medical science and improving therapeutic outcomes for patients. His work continues to inspire future innovations in the medical research landscape.

This text is generated by artificial intelligence and may not be accurate.